India plans to squeeze more from both patented drugs and generics
This article was originally published in Scrip
India is sending a clear message to drug-makers that it needs value-for-money from pharmaceuticals with two policy initiatives that aim directly to cut drug prices. One concerns a pricing system for patented medicines, while the other looks to expand the distribution of cut-price unbranded generic medicines around five-fold by the end of 2012, and 25-fold by the end of 2017.
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.